Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Saturday's Exclusive Content A Fresh IPO That Long-Term Investors Shouldn't IgnoreBy Jordan Chussler. First Published: 1/14/2026. 
Key Takeaways - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of the year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. Of course, IPOs carry substantial downside risk. Still, even conservative investors may find some recently public stocks that deserve a place in buy-and-hold portfolios. Amazon has quietly poured $144 million into a secretive AI chip company, and committed to buying a staggering $650 million of their product. Why? Because this obscure startup holds the key to unleashing the full potential of Nvidia's revolutionary Blackwell chip. Discover the company at the heart of the AI arms race. For one biotechnology company in the healthcare sector that recently went public, that may be the case. Last Year’s IPO Success Stories Last year illustrates why these companies shouldn’t be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. While short-term speculators captured a nearly 359% gain within the first 30 days of listing, longer-term holders have also benefited from strong returns. Others, such as Medline (NASDAQ: MDLN), refute the idea that IPOs are all high-risk startups. The medical products and services provider, which publicly debuted in December 2025, was founded in 1966, and already boasts a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. After its IPO, with shares beginning to trade on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnosis and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that can seek out particular cells, for example cancer cells, to deliver localized doses of radiation. That approach helps minimize damage to healthy tissue compared with some conventional radiation therapies. According to industry consultancy Grand View Research, the global nuclear medicine market was estimated at nearly $18 billion in 2024 and is forecast to reach nearly $35 billion by 2030—implying a compound annual growth rate (CAGR) of about 10.16%. Grand View Research also notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the dominant contributor—important context for Boston-based Aktis Oncology. Aktis Oncology’s Clinical-Stage Profile Wall Street expects biotech IPOs to rebound in 2026 after funding cuts by the Trump administration notably slowed healthcare-sector listings in 2025. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and produced one of the largest recent raises for a biotech offering. With $318 million raised in the IPO, the company now has a market capitalization of about $3.34 billion. According to the company’s prospectus, its executive team includes experts in drug development, regulatory approval, and commercialization, and management has participated in bringing 14 currently FDA-approved products to market. At a product level, Aktis develops targeted alpha radiopharmaceuticals—a class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology’s Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company. That did not deter investor interest—most notably from Eli Lilly (NYSE: LLY), which anchored the IPO. According to Reuters, Eli Lilly purchased $100 million of AKTS shares in the offering. That move builds on a 2024 partnership in which Lilly committed $60 million in cash and made an equity investment in Aktis, with potential milestone payments that could exceed $1 billion. The significance of Eli Lilly's backing should not be understated. With a market capitalization around $1.01 trillion, Lilly is one of the largest global pharmaceutical companies. Its net income rose nearly 109% year-over-year from 2023 to 2024, and the company is scheduled to report Q4 and full-year 2025 financial results on Feb. 5, which may further highlight its recent momentum. Between its equity stake and the $100 million in AKTS shares purchased at the IPO, the maker of Zepbound now has a sizable financial interest in the biotech startup’s success.
| 
